Vaxxilon Shares Transferred to Idorsia as part of the J&J Actelion Acquisition June 16, 2017
Actelion Ltd was the principal investor and majority shareholder of Vaxxilon AG since its inception in June 2015. In association with the Actelion acquisition by Janssen Holding GmbH, an indirect subsidiary of Johnson & Johnson, Actelion carried out a demerger of Actelion’s drug discovery and early clinical pipeline assets into Idorsia, a newly formed company, headquartered in Allschwil, Switzerland. The Vaxxilon shareholding was among these assets.
Peter Seeberger Presents at the Perlen der Forschung für die Anwendung January 13, 2017
Peter Seeberger had the opportunity to present the science, technology, and global health implications of synthetic carbohydrate vaccines at the scientific forum “Pearls of Research and Their Applications” hosted by Chancellor Angela Merkel.
Vaxxilon AG today announced that Arne von Bonin, PhD has been appointed to the role of Chief Scientific Officer (CSO). Dr. von Bonin is responsible for preclinical and early phase development for Vaxxilon’s multiple projects including the design, implementation and execution of proof of concept and toxicology studies, Phase 1/2 trials and associated regulatory filings.
Max Planck Gesellschaft Wissenschafts – Nachricht June 26, 2015
Das Unternehmen Impfstoffe
Die Max-Planck-Gesellschaft und Actelion gründen das Start-up-Unternehmen Vaxxilon, um Kohlenhydrat-basierte Impfstoffe zu kommerzialisieren
ACTELION PRESS RELEASE
Actelion creates Vaxxilon together with the Max Planck Society ALLSCHWIL, SWITZERLAND – 26 June 2015 – Actelion Ltd (SIX: ATLN) today announced the creation of a start-up, together with the Max Planck Society, in the field of synthetic carbohydrate vaccines.